Novavax President of R&D Filip Dubovsky to retire effective June 30, 2024

NOVAVAX INC

Dubovsky retires as President, R&D effective June 30, 2024.
Will provide consulting services for 12 months post-retirement at $15,000/month.
Company will pay COBRA premiums for up to 11 months.
Equity awards continue to vest during consulting period; unexercised options exercisable 90 days after.
Non-competition and non-solicitation covenants commence upon retirement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Filip Dubovsky

President, Research and Development

NVAX · NOVAVAX INC

Effective: 2024-06-30
Filed: May 23, 2024, 7:59 PM ET

On May 20, 2024, Filip Dubovsky notified Novavax, Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of June 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Filip Dubovsky retired as President, Research and Development at NOVAVAX INC.

Action: retired
Role: President, Research and Development

Exact text from the filing

On May 20, 2024, Filip Dubovsky notified Novavax, Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of June 30, 2024.

View on SEC.gov

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-24-064680

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.